Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
CGS/OGS Application for Masters of Medical Sciences Fall 2019 (Jae Hyun Byun)
FY 2018-19
Summary
The discovery of proprotein convertase subtilisin/kexin type-9 (PCSK9) has provided a novel therapeutic to combat against cardiovascular disease (CVD). Secreted by the liver, PCSK9 binds to cell-surface low-density lipoprotein (LDL) receptor to enhance its degradation, thereby reducing the capacity of the liver to clear LDL cholesterol (LDL-C) from circulation. Monoclonal antibodies targeted against PCSK9 have demonstrated to significantly reduce circulating LDL-C of approximately 50-60% in patients deemed high risk of cardiovascular events. Despite its initial success, the high cost in the manufacturing of these monoclonal antibodies provides context in the need for novel therapeutics and alternative modalities in the reduction of circulating PCSK9.
Genetic screens reveal that gain-of-function (GOF) mutations in the PCSK9 gene represent the third locus associated with autosomal-dominant hypercholesterolemia. Accordingly, individuals with the loss-of-function (LOF) variant exhibit increased expression of the hepatic LDL receptor (LDLR) and a concomitant reduction in circulating LDL-C levels. In particular, LOF variants including PCSK9 Q152H were identified and extensively studied due to the inability of endoplasmic reticulum (ER)-resident PCSK9 to undergo autocatalytic cleavage, an essential step for its maturation and secretion out of the ER. Thus, the retention of PCSK9 in the ER accounts for the increased LDLR expression and reduced circulating LDL-C levels attributed to the LOF variants.
As such, the focus of this study is to assess ER stress and liver toxicity as a potential consequence of retaining PCSK9 in the ER. Our findings will determine if this approach will represent a safe novel strategy to provide a cost-effective solution in combatting against CVD.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
406490
Name
Byun Jae Hyun
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
CGS/OGS Application for Masters of Medical Sciences Fall 2019 (Jae Hyun Byun)
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alirocumab/Evolocumab; Cardiovascular Disease; Endoplasmic Reticulum Stress; Grp78; Grp94; Ldl-Cholesterol; Low-Density Lipoprotein Receptor; Pcsk9; Pcsk9i; Unfolded Protein Response
Abstract
The discovery of proprotein convertase subtilisin/kexin type-9 (PCSK9) has provided a novel therapeutic to combat against cardiovascular disease (CVD). Secreted by the liver, PCSK9 binds to cell-surface low-density lipoprotein (LDL) receptor to enhance its degradation, thereby reducing the capacity of the liver to clear LDL cholesterol (LDL-C) from circulation. Monoclonal antibodies targeted against PCSK9 have demonstrated to significantly reduce circulating LDL-C of approximately 50-60% in patients deemed high risk of cardiovascular events. Despite its initial success, the high cost in the manufacturing of these monoclonal antibodies provides context in the need for novel therapeutics and alternative modalities in the reduction of circulating PCSK9.
Genetic screens reveal that gain-of-function (GOF) mutations in the PCSK9 gene represent the third locus associated with autosomal-dominant hypercholesterolemia. Accordingly, individuals with the loss-of-function (LOF) variant exhibit increased expression of the hepatic LDL receptor (LDLR) and a concomitant reduction in circulating LDL-C levels. In particular, LOF variants including PCSK9 Q152H were identified and extensively studied due to the inability of endoplasmic reticulum (ER)-resident PCSK9 to undergo autocatalytic cleavage, an essential step for its maturation and secretion out of the ER. Thus, the retention of PCSK9 in the ER accounts for the increased LDLR expression and reduced circulating LDL-C levels attributed to the LOF variants.
As such, the focus of this study is to assess ER stress and liver toxicity as a potential consequence of retaining PCSK9 in the ER. Our findings will determine if this approach will represent a safe novel strategy to provide a cost-effective solution in combatting against CVD.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Byun, Jae Hyun
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~